Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.

Abstract: The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.

Abstract: The present invention relates to a method for delivering exogenous mitochondria into cells and, more specifically, to a method for efficiently delivering, into the cytoplasm of target cells to be injected, mitochondria isolated from donor cells.

Abstract: A pipe connecting structure including a male flange block combined with a first pipe and a female flange block combined with a second pipe, which is fastened to the male flange block by a fastener, where a protrusion having a hole that communicates with the first pipe is formed through the male flange block, and an insert portion into which the protrusion is inserted is formed through the female flange block, and a sealing member to closely contact with the end face of the protrusion is seated on the bottom inside the insert portion, and the sealing member includes an inner sealing part of soft metal and an outer sealing part of rubber tightly fitted around the outer circumference of the inner sealing part.

Abstract: The present invention provides a pipe connecting structure including a male flange block combined with a first pipe and a female flange block combined with a second pipe, which is fastened to the male flange block by fastening means, where a protrusion having a hole that communicates with the first pipe is formed through the male flange block, and an insert portion into which the protrusion is inserted is formed through the female flange block, and a sealing member to closely contact with the end face of the protrusion is seated on the bottom inside the insert portion, and the sealing member includes an inner sealing part of soft metal and an outer sealing part of rubber tightly fitted around the outer circumference of the inner sealing part.